Antifungal micafungin launched

摘要

A new drug for the treatment of serious fungal infections has been launched by Astellas Pharma.Micafungin(marketed as Mycamine)is intravenously administered and is indicated-for patients of any age,including neonates and the elderly-for the treatment of invasive candidiasis,and as prophylaxis against Candida infection for patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia for 10 or more days.It is also indicated for the treatment of oesophageal candidiasis in patients aged 16 years and older for whom intravenous therapy is appropriate.